Pancreatic Cancer Research

ResearcherKeio UniversityNo recent work listed

Michiie Sakamoto

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3507-7369; OpenAlex author ID A5091811703. Sources: OpenAlex.

Their work

Papers
15 (first author 0, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
50
Papers, trials and grants by year

2013: 1 paper · 2014: 2 papers · 2015: 2 papers · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper

Papers 15

  1. Post-operative mortality and recurrence patterns in pancreatic cancer according to KRAS mutation and CDKN2A, p53, and SMAD4 expression. Last author DOI 10.1002/cjp2.323↗
  2. KRAS variant allele frequency, but not mutation positivity, associates with survival of patients with pancreatic cancer. Co-author DOI 10.1111/cas.15398↗
  3. Three Distinct Stroma Types in Human Pancreatic Cancer Identified by Image Analysis of Fibroblast Subpopulations and Collagen-Response. Last author DOI 10.1158/1078-0432.ccr-21-3693↗
  4. Three Distinct Stroma Types in Human Pancreatic Cancer Identified by Image Analysis of Fibroblast Subpopulations and Collagen. Last author DOI 10.1158/1078-0432.ccr-20-2298↗
  5. Peritoneal dissemination of pancreatic cancer caused by endoscopic ultrasound-guided fine needle aspiration: A case report and literature review. Co-author DOI 10.3748/wjg.v27.i3.294↗
  6. Discovery of Pancreatic Ductal Adenocarcinoma-Related Aberrant Glycosylations: A Multilateral Approach of Lectin Microarray-Based Tissue Glycomic Profiling Wit… Co-author DOI 10.3389/fonc.2020.00338↗
  7. O-Glycan-Altered Extracellular Vesicles: A Specific Serum Marker Elevated in Pancreatic Cancer. Co-author DOI 10.3390/cancers12092469↗
  8. Characterization of spatial distribution of tumor-infiltrating CD8+ T cells refines their prognostic utility for pancreatic cancer survival. Last author DOI 10.1038/s41379-019-0291-z↗
  9. Mesenchymal-epithelial transition of pancreatic cancer cells at perineural invasion sites is induced by Schwann cells. Last author DOI 10.1111/pin.12641↗
  10. Two cases of pancreatic ductal adenocarcinoma with intrapancreatic metastasis. Co-author DOI 10.3748/wjg.v22.i41.9222↗
  11. Upregulation of integrin β4 promotes epithelial-mesenchymal transition and is a novel prognostic marker in pancreatic ductal adenocarcinoma. Last author DOI 10.1038/labinvest.2014.166↗
  12. Two Cases of Pathological Complete Response to Neoadjuvant Chemoradiation Therapy in Pancreatic Cancer. Co-author DOI 10.2302/kjm.2014-0014-cr↗
  13. Presence of primary cilia in cancer cells correlates with prognosis of pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.humpath.2013.11.017↗
  14. Upregulated SMAD3 promotes epithelial-mesenchymal transition and predicts poor prognosis in pancreatic ductal adenocarcinoma. Last author DOI 10.1038/labinvest.2014.53↗
  15. Mesenchymal stem cells regulate epithelial-mesenchymal transition and tumor progression of pancreatic cancer cells. Co-author DOI 10.1111/cas.12059↗

Closest collaborators

The 25 strongest of 50 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yohei Masugi · 15 shared papers, 2013–2023 · strength 1.30
  2. Minoru Kitago · 11 shared papers, 2014–2023 · strength 0.90
  3. Ken Yamazaki · 7 shared papers, 2014–2022 · strength 0.66
  4. Yuko Kitagawa · 9 shared papers, 2013–2021 · strength 0.53
  5. Yoko Fujii‐Nishimura · 5 shared papers, 2015–2021 · strength 0.39
  6. Shutaro Hori · 3 shared papers, 2020–2021 · strength 0.30
  7. Yutaka Nakano · 3 shared papers, 2020–2022 · strength 0.29
  8. Yuta Abe · 4 shared papers, 2015–2021 · strength 0.28
  9. Yosuke Inoue · 2 shared papers, 2022–2023 · strength 0.24
  10. Kiyoshi Hasegawa · 2 shared papers, 2022–2023 · strength 0.24
  11. Manabu Takamatsu · 2 shared papers, 2022–2023 · strength 0.24
  12. Tsuyoshi Takeda · 2 shared papers, 2022–2023 · strength 0.24
  13. Tatsunori Suzuki · 2 shared papers, 2022–2023 · strength 0.24
  14. Tsuyoshi Hamada · 2 shared papers, 2022–2023 · strength 0.24
  15. Yu Takahashi · 2 shared papers, 2022–2023 · strength 0.24
  16. Sho Uemura · 2 shared papers, 2022–2023 · strength 0.24
  17. Yousuke Nakai · 2 shared papers, 2022–2023 · strength 0.24
  18. Mitsuhiro Fujishiro · 2 shared papers, 2022–2023 · strength 0.24
  19. Naoki Sasahira · 2 shared papers, 2022–2023 · strength 0.24
  20. Atsushi Matsuda · 2 shared papers, 2020 · strength 0.19
  21. Atsushi Kuno · 2 shared papers, 2020 · strength 0.19
  22. Yusuke Fujita · 2 shared papers, 2016–2019 · strength 0.14
  23. Yuki Hirose · 1 shared paper, 2023 · strength 0.13
  24. Gaku Shimane · 1 shared paper, 2023 · strength 0.13
  25. Atsushi Oba · 1 shared paper, 2023 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.